Brain scan study tests new depression Drug's target binding
NCT ID NCT07329621
First seen Jan 10, 2026 · Last updated May 25, 2026 · Updated 23 times
Summary
This early-phase study tests how well the experimental drug MSP-2020 attaches to serotonin receptors in the brains of 18 healthy men. Researchers will use PET scans to measure receptor occupancy and track the drug's levels in the blood. The goal is to gather safety and dosing information for future depression treatment studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INCOMPLETE RESPONSE - MAJOR DEPRESSIVE DISORDER (IR-MDD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
HMR Hammersmith Medicines Research Ltd.
RECRUITINGLondon, United Kingdom
Conditions
Explore the condition pages connected to this study.